diabetics
Takeda Filed for US Approval of Diabetes Drug Alogliptin
Filed in archive News , Treatment by Gloria Gamat on January 4, 2008
The Japanese pharmaceutical company - Takeda - announced that it is seeking U.S. approval of its diabetes Drug Alogliptin (SYR-322).

Takeda Filed for US Approval of Diabetes Drug Alogliptin


Alogliptin is a diabetes drug that Takeda hopes to replace Actos (Pioglitazone HCl) - another Takeda diabetes drug.

[Alogliptin, or SYR-322, is in a new class of oral agents for the treatment of type 2 diabetes, called DPP-4 inhibitor, regulating blood glucose levels, and the class also includes Merck & Co's Januvia and Novartis AG's Galvus]

According to Takeda spokesman Toshiyuki Ikeuchi:

"We are hoping Alogliptin to boost our diabetes franchise, which is a very important field for us."
The approval process is expected to take about a year."


Find more details from the UK Guardian.



Permalink: Takeda Filed for US Approval of Diabetes Drug Alogliptin
Tags: Actos  Alogliptin  SYR322  Takeda  Pharmaceuticals  diabetes  drug  DPP4  inhibitor  takeda  diabetes+drug 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/109458
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for Takeda Filed for US Approval of Diabetes Drug Alogliptin:

  • Currently 6.33/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 6.33 out of 3 vote(s) cast.
Subscribe
Share It
Popular posts from our other blogs:
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!